Startseite
arznei-telegramm®  12/2016

THERAPY FROM A CRITICAL VIEWPOINT
Celecoxib (CELEBREX, generics) - as safe as naproxen and ibuprofen regarding cardiovascular events?
Prevention of thromboembolism after knee arthroscopy or lower-leg casting
Rivaroxaban for patients with atrial fibrillation undergoing placement of stents: doubtful benefits compared with warfarin

a-t READERS QUESTIONS AND COMMENTS
Adjuvanted flu vaccine FLUAD … clinical efficacy benefits still not proven
Carotis plaques detected by screening in healthy people - what should you do?
Restrict package size for colchicine preparations

IN BRIEF
USA: warning notice for homoeopathics
Pfizer/UK: 100 million € fine because of high prices

CURRENT ADR NETWORK REPORT
Angioedema and other intolerance reactions with oral lavendula oil (LASEA)

SIDE EFFECTS
Unusual coloured urine due to drugs

e a-t ON THE INTERNET
Hepatitis C: sofosbuvir plus velpatasvir (EPCLUSA